PoNS

Helius Medical Technologies has extended by six months a program that allows multiple sclerosis (MS) patients in the U.S. to access its Portable Neuromodulation Stimulator (PoNS) device at a reduced cost. The Patient Therapy Access Program (PTAP) partly subsidizes the cost of using PoNS — an…

An upcoming observational clinical trial will assess how adherence to treatment with the portable neuromodulation stimulator (PoNS) device, used in the clinic and later at home, improves gait in people with multiple sclerosis (MS). Sponsored by Helius Medical Technologies, the device’s developer, the open-label Therapeutic…

PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available on the U.S. market early next year, its developer, Helius Medical Technologies, announced in a quarterly financial update. Short for Portable Neuromodulation Stimulator, the PoNS…

SPMS Patient First to Be Treated With Antibody Given via Nasal Spray How great is this? As someone who gave himself an injection in his thigh for many years and received IV infusions for many more, an MS antibody treatment sprayed into the nose is wonderful news. This approval…

The U.S. Food and Drug Administration (FDA) has authorized the use of a medical device called Portable Neuromodulation Stimulator or PoNS as a short-term treatment for walking difficulties in people with multiple sclerosis (MS). PoNS, developed by Helius Medical Technologies, is a non-invasive medical device…

Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request for more information about the company’s application for de novo classification and clearance of its portable neuromodulation stimulator (PoNS) device to help treat walking difficulties in people…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Helius Medical Technologies’ portable neuromodulation stimulator (PoNS) for the treatment of walking impairments in multiple sclerosis (MS) patients. The device, which is meant to be used…

Editor’s note: Tamara Sellman continues her occasional series on the “MS alphabet” with this column referencing terms starting with the letter P. This post comes third in a series of seven. Symptoms of MS Pseudoexacerbation Sometimes a person with MS may feel they…

Multiple sclerosis (MS) patients given gentle electrical stimulation to their tongues during physical and cognitive rehabilitation training benefited more than those who did not have the stimulation, a small pilot study demonstrated. Those who received the weak stimulation had significant improvements in balance and better scores than controls in cognition and other…

Helius Medical Technologies‘s Portable Neuromodulation Stimulator (PoNS), a device being developed to treat neuroplasticity in people with multiple sclerosis (MS) and other neurological diseases, has been recommended for ISO 13485 certification, an international standard of quality management for medical devices, after a positive evaluation by Lloyd’s Register Quality Assurance Limited (LRQA). This…

Helius Medical Technologies announced results of a pilot study, demonstrating the benefits of PoNS Therapy — a combination of the investigational Portable Neuromodulation Stimulator (PoNS) device with physical therapy — in patients with advanced multiple sclerosis (MS). Specifically, the treatment was seen to improve both patients’ quality of life, and physical and…

Multiple Sclerosis News Today has reported the latest therapies, clinical trial developments, and events in multiple sclerosis (MS) on a daily basis throughout the past year. As 2015 comes to an end, here are the year’s 10 articles most widely read by  Multiple Sclerosis News Today readers, each with a brief summary of the developments…

Helius Medical Technologies, Inc., a company dedicated to neurological wellness, recently announced that the multiple sclerosis (MS) pilot study assessing the company’s investigational Portable Neuromodulation Stimulator (PoNS™) device has met all of the study’s goals. PoNS is a non-invasive device that allows the delivery of neurostimulation through the…

Newtown, Pennsylvania based Helius Medical Technologies, Inc. announced on June 6th that the company has entered into an agreement and plan of merger whereby the Company has agreed to acquire 100% of issued and outstanding common shares of Neurohabilitation Corporation (“Neuro”) of Delaware by way of a plan of…